Biophytis SA is a holding company. It engages in the clinical development of therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. The firm develops drug candidates targeting diseases of aging. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.